Everything below concerns sublimation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-18. Numbers and descriptions here follow the published literature rather than marketing material.
The physics of freeze-drying couples heat transfer, mass transfer, and phase change. Heat supplied through the shelf must reach the sublimation front without melting the ice or degrading the product. Water vapor then travels through the already dried layer and leaves the chamber, where low pressure and cold traps keep it from returning. The dried layer acts as a resistance to vapor flow, so drying rate changes as the front recedes. Open questions remain about how pore structure and formulation heterogeneity affect drying uniformity at larger scales.
Lyophilization removes water from a frozen material by sublimation under reduced pressure. The process begins with freezing, which converts liquid water into ice and concentrates dissolved solids. Primary drying then lowers chamber pressure so ice changes directly into vapor without passing through a liquid phase. Secondary drying raises the shelf temperature to remove bound water that remains after ice sublimation. The result is a dry, porous structure that can be reconstituted later.
Formulation composition influences whether freeze-drying produces an intact cake or a collapsed mass. Excipients such as sugars and polymers can raise the collapse temperature and provide bulk during drying. The critical temperature for primary drying is often the collapse temperature or the glass transition temperature of the maximally concentrated phase. If the product temperature exceeds this threshold, the frozen matrix may soften and lose structure. Established practice therefore links shelf temperature and chamber pressure to the formulation's thermal properties.
Industries use lyophilization for pharmaceuticals, biological products, and food preservation. In the pharmaceutical sector, it extends the shelf life of injectable drugs, vaccines, and proteins that are unstable in aqueous solution. Food manufacturers apply freeze-drying to coffee, fruits, and ready meals to retain flavor and texture. The process is energy-intensive and requires specialized equipment, which limits its use to high-value products. Ongoing research examines how formulation and process parameters affect the quality of the final dried product.
Lyophilization, also known as freeze-drying, is a process that removes water from a material by freezing it and then reducing pressure to allow ice to sublimate directly into vapor. The method begins with a freezing step that solidifies the water content. Next, primary drying lowers the pressure below the triple point of water, enabling sublimation without passing through a liquid phase. A final secondary drying step removes bound water through desorption. This sequence produces a dry, porous cake that can be reconstituted later.
| Property | Value | Notes |
|---|---|---|
| Common name | Freeze-drying | Process removes water by sublimation under vacuum. |
| Typical primary drying shelf temperature | -40 C to -10 C | Set below the formulation's collapse temperature. |
| Typical chamber pressure | 0.05-0.3 mbar | Low pressure allows ice to sublime below its triple point. |
| Water content after drying | 0.5-3% by weight | Higher values may reduce storage stability for some materials. |
| Key thermal parameter | Collapse temperature | Measured by freeze-drying microscopy or differential scanning calorimetry. |
The process generally proceeds in three stages: freezing, primary drying, and secondary drying. During freezing, controlled cooling converts water into ice and may also crystallize or vitrify solutes. In primary drying, the pressure is lowered below the triple point, and heat is supplied so ice sublimes directly to vapor. Secondary drying removes water that remains bound to the solid matrix, yielding a low final water content. Product temperature must stay below the collapse or glass transition temperature to maintain structure. Cycle design therefore balances shelf temperature, chamber pressure, and time.
Freeze-drying is used for materials whose activity or structure depends on low temperature and low water content. Examples include certain biologics, diagnostic reagents, starter cultures, coffee, and porous inorganic precursors. The dried product forms a cake whose porosity aids rapid wetting and dissolution. Main drawbacks are high energy use, long cycle times, and sensitivity to formulation and equipment variation. Questions remain about how freezing rates and ice morphology affect batch uniformity, especially when moving from laboratory to production scale.
Lyophilization, also called freeze-drying, is a dehydration process in which a solvent, usually water, is frozen and then removed by sublimation under reduced pressure. The method preserves heat-sensitive materials that would degrade in conventional drying. Large-scale use grew during the mid-twentieth century for blood plasma and antibiotics, and it later expanded to vaccines, enzymes, foods, and advanced materials. The process produces a dry, porous solid that usually reconstitutes rapidly. It is distinct from simple evaporation because the solvent bypasses the liquid phase during primary removal.
Lyophilization is a drying process in which a solvent, usually water, is removed from a frozen material by sublimation under reduced pressure. The material is first solidified, then placed under vacuum so that ice transitions directly to vapor without a bulk liquid phase. This approach suits heat-sensitive substances that would degrade during conventional evaporation. Primary drying removes unbound ice, while secondary drying reduces water that remains adsorbed to the solid matrix. The result is a porous, lightweight solid that can be reconstituted later.
A typical cycle begins with freezing, sometimes including an annealing step to control ice crystal size. Freezing conditions influence the pore network that later allows vapor escape. During primary drying, shelf temperature and chamber pressure are set so heat enters the product while its temperature stays below the collapse or eutectic point. Secondary drying then raises the shelf temperature to desorb bound water and lower residual moisture. Cycle design depends on formulation, fill volume, container type, and equipment capability.
=== Plastics and building materials === In one large-scale application, melamine is combined with formaldehyde and other agents to produce melamine resins. Such resins are characteristically durable thermosetting plastic used in high-pressure decorative laminates such as Wilsonart, melamine dinnerware, laminate flooring, and dry erase boards. Melamine cookware is not microwave-safe, and can be identified from the fact it is "slightly heavier and noticeably thicker than its plastic counterparts." Melamine foam is used as insulation, soundproofing material and in polymeric cleaning products, such as Magic Eraser. Melamine is one of the major components in Pigment Yellow 150, a colorant in inks and plastics. Melamine also is used in the fabrication of melamine polysulfonate, used as a superplasticizer for making high-resistance concrete. Sulfonated melamine formaldehyde (SMF) is a polymer used as a cement admixture to reduce the water content in concrete while increasing the fluidity and the workability of the mix during handling and pouring. It results in concrete with a lower porosity and a higher mechanical strength, exhibiting an improved resistance to aggressive environments and a longer lifetime.
== Function == Amylin functions as part of the endocrine pancreas and contributes to glycemic control. The peptide is secreted from the pancreatic islets into the blood circulation and is cleared by peptidases in the kidney. It is not found in the urine. Amylin's metabolic function is well-characterized as an inhibitor of the appearance of nutrient [especially glucose] in the plasma. It thus functions as a synergistic partner to insulin, with which it is cosecreted from pancreatic beta cells in response to meals. The overall effect is to slow the rate of appearance (Ra) of glucose in the blood after eating; this is accomplished via coordinate slowing down gastric emptying, inhibition of digestive secretion [gastric acid, pancreatic enzymes, and bile ejection], and a resulting reduction in food intake. Appearance of new glucose in the blood is reduced by inhibiting secretion of the gluconeogenic hormone glucagon. These actions, which are mostly carried out via a glucose-sensitive part of the brain stem, the area postrema, may be over-ridden during hypoglycemia. They collectively reduce the total insulin demand. Amylin also acts in bone metabolism, along with the related peptides calcitonin and calcitonin gene related peptide. Rodent amylin knockouts do not have a normal reduction of appetite following food consumption. Because it is an amidated peptide, like many neuropeptides, it is believed to be responsible for the effect on appetite.
fkbB enzyme is responsible of allylmalonyl-CoA synthesis or possibly propionylmalonyl-CoA at C21, which it is an unusual step of general PKS 1. As mentioned, if two methoxymalonyl CoA molecules are substituted for two malonyl-CoA molecules, they will take place in module 7 and 8 (C13 and C15), and fkbA enzyme will enforce this process. After the last step (module 10) of PKS 1, one molecule of L-pipecolic acid formed from L-lysine and catalyzed through fkbL enzyme synthesizes with the molecule from the module 10. The process of L-pipecolic acid synthesis is NRPS enforced by fkbP enzyme. After synthesizing the entire subunits, the molecule is cyclized. After the cyclization, the pre-tacrolimus molecule goes through the post-synthase tailoring steps such as oxidation and S-adenosyl methionine. Particularly fkbM enzyme is responsible of alcohol methylation targeting the alcohol of DHCHC starter unit (Carbon number 31 depicted in brown), and fkbD enzyme is responsible of C9 (depicted in green). After these tailoring steps, the tacrolimus molecule becomes biologically active.
=== 1987 === January 16: Natives within the Party who oppose his policies of economic redevelopment (Perestroika). It is Gorbachev's hope that through initiatives of openness, debate and participation, that the Soviet people will support Perestroika. February 25: Phosphorite War breaks out in Estonia. April 15: An insurrection occurred in Sri Lanka by the Marxist–Leninist group, JVP. June 12: During a visit to West Berlin, U.S. President Ronald Reagan challenges Soviet General Secretary Mikhail Gorbachev in a speech: "Mr. Gorbachev, tear down this wall!" (The Berlin Wall). June 15: Famous Italian Singer and Songwriter Adriano Celentano lands in Moscow to present his movie Joan Lui in Soviet theaters, another step that opens the Soviet world to the Western one. September 10: The Battle of Cuito Cuanavale, Angola begins and further intensifies the South African Border War. September 30: Mohammad Najibullah becomes President of Afghanistan and implements a policy of National Reconciliation as a means of putting an end to the Soviet–Afghan War as well as beginning an end to Soviet influence in the country. December: A short war was fought between Thailand and Laos. December 8: The Intermediate-Range Nuclear Forces Treaty is signed in Washington, D.C. by U.S. President Ronald Reagan and Soviet leader Mikhail Gorbachev. Some later claim this was the unofficial beginning of the end of the Cold War. Gorbachev agrees to START I treaty. December 9: The First Intifada was waged by Palestinians against the Israeli government.
A partial vacuum may be generated by increasing the volume of a container. To continue evacuating a chamber indefinitely without requiring infinite growth, a compartment of the vacuum can be repeatedly closed off, exhausted, and expanded again. This is the principle behind a positive displacement pump, for example the manual water pump. Inside the pump, a mechanism expands a small sealed cavity to reduce its pressure below that of the atmosphere. Because of the pressure differential, some fluid from the chamber (or the well, in our example) is pushed into the pump's small cavity. The pump's cavity is then sealed from the chamber, opened to the atmosphere, and squeezed back to a minute size. More sophisticated systems are used for most industrial applications, but the basic principle of cyclic volume removal is the same:
Sources: en.wikipedia.org
=== EC 2.3.1: Transferring groups other than amino-acyl groups === EC 2.3.1.1: amino-acid N-acetyltransferase EC 2.3.1.2: imidazole N-acetyltransferase EC 2.3.1.3: glucosamine N-acetyltransferase EC 2.3.1.4: glucosamine-phosphate N-acetyltransferase EC 2.3.1.5: arylamine N-acetyltransferase EC 2.3.1.6: choline O-acetyltransferase EC 2.3.1.7: carnitine O-acetyltransferase EC 2.3.1.8: phosphate acetyltransferase EC 2.3.1.9: acetyl-CoA C-acetyltransferase EC 2.3.1.10: hydrogen-sulfide S-acetyltransferase EC 2.3.1.11: thioethanolamine S-acetyltransferase EC 2.3.1.12: dihydrolipoyllysine-residue acetyltransferase EC 2.3.1.13: glycine N-acyltransferase EC 2.3.1.14: glutamine N-phenylacetyltransferase EC 2.3.1.15: glycerol-3-phosphate O-acyltransferase EC 2.3.1.16: acetyl-CoA C-acyltransferase EC 2.3.1.17: aspartate N-acetyltransferase EC 2.3.1.18: galactoside O-acetyltransferase EC 2.3.1.19: phosphate butyryltransferase EC 2.3.1.20: diacylglycerol O-acyltransferase EC 2.3.1.21: carnitine O-palmitoyltransferase EC 2.3.1.22: 2-acylglycerol O-acyltransferase EC 2.3.1.23: 1-acylglycerophosphocholine O-acyltransferase EC 2.3.1.24: sphingosine N-acyltransferase EC 2.3.1.25: plasmalogen synthase EC 2.3.1.26: sterol O-acyltransferase EC 2.3.1.27: cortisol O-acetyltransferase EC 2.3.1.28: chloramphenicol O-acetyltransferase EC 2.3.1.29: glycine C-acetyltransferase EC 2.3.1.30: serine O-acetyltransferase EC 2.3.1.31: homoserine O-acetyltransferase EC 2.3.1.32: lysine N-acetyltransferase EC 2.3.1.33: histidine N-acetyltransferase EC 2.3.1.34: D-tryptophan N-acetyltransferase EC 2.3.1.35: glutamate N-acetyltransferase EC 2.3.1.36: D-amino-acid N-acetyltransferase EC 2.3.1.37: 5-aminolevulinate synthase EC 2.3.1.38: [acyl-carrier-protein] S-acetyltransferase EC 2.3.1.39: [acyl-carrier-protein] S-malonyltransferase EC 2.3.1.40: acyl-[acyl-carrier-protein]—phospholipid O-acyltransferase EC 2.3.1.41: β-ketoacyl-[acyl-carrier-protein] synthase I EC 2.3.1.42: glycerone-phosphate O-acyltransferase EC 2.3.1.43: phosphatidylcholine—sterol O-acyltransferase EC 2.3.1.44: N-acetylneuraminate 4-O-acetyltransferase EC 2.3.1.45: N-acetylneuraminate 7-O(or 9-O)-acetyltransferase EC 2.3.1.46: homoserine O-succinyltransferase EC 2.3.1.47: 8-amino-7-oxononanoate synthase EC 2.3.1.48: histone acetyltransferase EC 2.3.1.49: deacetyl-(citrate-(pro-3S)-lyase) S-acetyltransferase EC 2.3.1.50: serine C-palmitoyltransferase EC 2.3.1.51: 1-acylglycerol-3-phosphate O-acyltransferase EC 2.3.1.52: 2-acylglycerol-3-phosphate O-acyltransferase EC 2.3.1.53: phenylalanine N-acetyltransferase EC 2.3.1.54: formate C-acetyltransferase EC 2.3.1.55: identical to EC 2.3.1.82 EC 2.3.1.56: aromatic-hydroxylamine O-acetyltransferase EC 2.3.1.57: diamine N-acetyltransferase EC 2.3.1.58: 2,3-diaminopropionate N-oxalyltransferase EC 2.3.1.59: gentamicin 2′-N-acetyltransferase EC 2.3.1.60: gentamicin 3′-N-acetyltransferase EC 2.3.1.61: dihydrolipoyllysine-residue succinyltransferase EC 2.3.1.62: 2-acylglycerophosphocholine O-acyltransferase EC 2.3.1.63: 1-alkylglycerophosphocholine O-acyltransferase EC 2.3.1.64: agmatine N4-coumaroyltransferase EC 2.3.1.65: bile acid-CoA:amino acid N-acyltransferase EC 2.3.1.66: leucine N-acetyltransferase EC 2.3.1.67: 1-alkylglycerophosphocholine O-acetyltransferase EC 2.3.1.68: glutamine N-acyltransferase EC 2.3.1.69: monoterpenol O-acetyltransferase EC 2.3.1.70: deleted EC 2.3.1.71: glycine N-benzoyltransferase EC 2.3.1.72: indoleacetylglucose—inositol O-acyltransferase EC 2.3.1.73: diacylglycerol—sterol O-acyltransferase EC 2.3.1.74: chalcone synthase EC 2.3.1.75: long-chain-alcohol O-fatty-acyltransferase EC 2.3.1.76: retinol O-fatty-acyltransferase EC 2.3.1.77: triacylglycerol—sterol O-acyltransferase EC 2.3.1.78: heparan-α-glucosaminide N-acetyltransferase EC 2.3.1.79: maltose O-acetyltransferase EC 2.3.1.80: cysteine-S-conjugate N-acetyltransferase EC 2.3.1.81: aminoglycoside 3-N-acetyltransferase EC 2.3.1.82: aminoglycoside 6′-N-acetyltransferase EC 2.3.1.83: phosphatidylcholine—dolichol O-acyltransferase EC 2.3.1.84: alcohol O-acetyltransferase EC 2.3.1.85: fatty-acid synthase system EC 2.3.1.86: fatty-acyl-CoA synthase system EC 2.3.1.87: aralkylamine N-acetyltransferase EC 2.3.1.88: Now covered by EC 2.3.1.254, EC 2.3.1.255, EC 2.3.1.256, EC 2.3.1.257, EC 2.3.1.258 and EC 2.3.1.259 EC 2.3.1.89: tetrahydrodipicolinate N-acetyltransferase EC 2.3.1.90: β-glucogallin O-galloyltransferase EC 2.3.1.91: sinapoylglucose—choline O-sinapoyltransferase EC 2.3.1.92: sinapoylglucose—malate O-sinapoyltransferase EC 2.3.1.93: 13-hydroxylupinine O-tigloyltransferase EC 2.3.1.94: 6-deoxyerythronolide-B synthase EC 2.3.1.95: trihydroxystilbene synthase EC 2.3.1.96: glycoprotein N-palmitoyltransferase EC 2.3.1.97: glycylpeptide N-tetradecanoyltransferase EC 2.3.1.98: chlorogenate—glucarate O-hydroxycinnamoyltransferase EC 2.3.1.99: quinate O-hydroxycinnamoyltransferase EC 2.3.1.100: [myelin-proteolipid] O-palmitoyltransferase EC 2.3.1.101: formylmethanofuran—tetrahydromethanopterin N-formyltransferase EC 2.3.1.102: N6-hydroxylysine O-acetyltransferase EC 2.3.1.103: sinapoylglucose—sinapoylglucose O-sinapoyltransferase EC 2.3.1.104: The activity is covered by EC 2.3.1.25 EC 2.3.1.105: alkylglycerophosphate 2-O-acetyltransferase EC 2.3.1.106: tartronate O-hydroxycinnamoyltransferase EC 2.3.1.107: deacetylvindoline O-acetyltransferase EC 2.3.1.108: α-tubulin N-acetyltransferase EC 2.3.1.109: arginine N-succinyltransferase EC 2.3.1.110: tyramine N-feruloyltransferase EC 2.3.1.111: mycocerosate synthase EC 2.3.1.112: D-tryptophan N-malonyltransferase EC 2.3.1.113: anthranilate N-malonyltransferase EC 2.3.1.114: 3,4-dichloroaniline N-malonyltransferase EC 2.3.1.115: isoflavone-7-O-β-glucoside 6′′-O-malonyltransferase EC 2.3.1.116: flavonol-3-O-β-glucoside O-malonyltransferase EC 2.3.1.117: 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase EC 2.3.1.118: N-hydroxyarylamine O-acetyltransferase EC 2.3.1.119: Now covered by EC 2.3.1.199, EC 1.1.1.330, EC 4.2.1.134 and EC 1.3.1.93 EC 2.3.1.120: The reaction is due to EC 2.3.1.74 EC 2.3.1.121: 1-alkenylglycerophosphoethanolamine O-acyltransferase EC 2.3.1.122: trehalose O-mycolyltransferase EC 2.3.1.123: dolichol O-acyltransferase EC 2.3.1.124: Already listed as EC 2.3.1.20 EC 2.3.1.125: 1-alkyl-2-acetylglycerol O-acyltransferase EC 2.3.1.126: isocitrate O-dihydroxycinnamoyltransferase EC 2.3.1.127: ornithine N-benzoyltransferase EC 2.3.1.128: now classified as EC 2.3.1.266 and EC 2.3.1.267 EC 2.3.1.129: acyl-[acyl-carrier-protein]—UDP-N-acetylglucosamine O-acyltransferase EC 2.3.1.130: galactarate O-hydroxycinnamoyltransferase EC 2.3.1.131: glucarate O-hydroxycinnamoyltransferase EC 2.3.1.132: glucarolactone O-hydroxycinnamoyltransferase EC 2.3.1.133: shikimate O-hydroxycinnamoyltransferase EC 2.3.1.134: galactolipid O-acyltransferase EC 2.3.1.135: phosphatidylcholine—retinol O-acyltransferase EC 2.3.1.136: polysialic-acid O-acetyltransferase EC 2.3.1.137: carnitine O-octanoyltransferase EC 2.3.1.138: putrescine N-hydroxycinnamoyltransferase EC 2.3.1.139: ecdysone O-acyltransferase EC 2.3.1.140: rosmarinate synthase EC 2.3.1.141: galactosylacylglycerol O-acyltransferase EC 2.3.1.142: glycoprotein O-fatty-acyltransferase EC 2.3.1.143: β-glucogallin—tetrakisgalloylglucose O-galloyltransferase EC 2.3.1.144: anthranilate N-benzoyltransferase EC 2.3.1.145: piperidine N-piperoyltransferase EC 2.3.1.146: pinosylvin synthase EC 2.3.1.147: glycerophospholipid arachidonoyl-transferase (CoA-independent) EC 2.3.1.148: glycerophospholipid acyltransferase (CoA-dependent) EC 2.3.1.149: platelet-activating factor acetyltransferase EC 2.3.1.150: salutaridinol 7-O-acetyltransferase EC 2.3.1.151: 2,3′,4,6-tetrahydroxybenzophenone synthase EC 2.3.1.152: alcohol O-cinnamoyltransferase EC 2.3.1.153: anthocyanin 5-(6′′′-hydroxycinnamoyltransferase) EC 2.3.1.154: Now EC 2.3.1.176 EC 2.3.1.155: acetyl-CoA C-myristoyltransferase EC 2.3.1.156: phloroisovalerophenone synthase EC 2.3.1.157: glucosamine-1-phosphate N-acetyltransferase EC 2.3.1.158: phospholipid:diacylglycerol acyltransferase EC 2.3.1.159: acridone synthase EC 2.3.1.160: vinorine synthase EC 2.3.1.161: lovastatin nonaketide synthase EC 2.3.1.162: taxadien-5α-ol O-acetyltransferase EC 2.3.1.163: 10-hydroxytaxane O-acetyltransferase EC 2.3.1.164: isopenicillin-N N-acyltransferase EC 2.3.1.165: 6-methylsalicylic acid synthase EC 2.3.1.166: 2α-hydroxytaxane 2-O-benzoyltransferase EC 2.3.1.167: 10-deacetylbaccatin III 10-O-acetyltransferase EC 2.3.1.168: dihydrolipoyllysine-residue (2-methylpropanoyl)transferase EC 2.3.1.169: CO-methylating acetyl-CoA synthase EC 2.3.1.170: 6′-deoxychalcone synthase EC 2.3.1.171: anthocyanin 6′′-O-malonyltransferase EC 2.3.1.172: anthocyanin 5-O-glucoside 6′′′-O-malonyltransferase EC 2.3.1.173: flavonol-3-O-triglucoside O-coumaroyltransferase EC 2.3.1.174: 3-oxoadipyl-CoA thiolase EC 2.3.1.175: deacetylcephalosporin-C acetyltransferase EC 2.3.1.176: propanoyl-CoA C-acyltransferase EC 2.3.1.177: 3,5-dihydroxybiphenyl synthase EC 2.3.1.178: diaminobutyrate acetyltransferase EC 2.3.1.179: β-ketoacyl-[acyl-carrier-protein] synthase II EC 2.3.1.180: β-ketoacyl-[acyl-carrier-protein] synthase III EC 2.3.1.181: lipoyl(octanoyl) transferase EC 2.3.1.182: Now covered by EC 2.3.3.21 EC 2.3.1.183: phosphinothricin acetyltransferase EC 2.3.1.184: acyl-homoserine-lactone synthase EC 2.3.1.185: tropine acyltransferase EC 2.3.1.186: pseudotropine acyltransferase EC 2.3.1.187: acetyl-S-ACP:malonate ACP transferase EC 2.3.1.188: ω-hydroxypalmitate O-feruloyl transferase EC 2.3.1.189: mycothiol synthase EC 2.3.1.190: acetoin dehydrogenase EC 2.3.1.191: UDP-3-O-(3-hydroxyacyl)glucosamine N-acyltransferase EC 2.3.1.192: glycine N-phenylacetyltransferase EC 2.3.1.193: tRNAMetcytidine acetyltransferase EC 2.3.1.194: acetoacetyl-CoA synthase EC 2.3.1.195: (Z)-3-hexen-1-ol acetyltransferase EC 2.3.1.196: benzyl alcohol O-benzoyltransferase EC 2.3.1.197: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose 3-N-acetyltransferase EC 2.3.1.198: glycerol-3-phosphate 2-O-acyltransferase EC 2.3.1.199: very-long-chain 3-oxoacyl-CoA synthase EC 2.3.1.200: lipoyl amidotransferase EC 2.3.1.201: UDP-2-acetamido-3-amino-2,3-dideoxy-glucuronate N-acetyltransferase EC 2.3.1.202: UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine N-acetyltransferase EC 2.3.1.203: UDP-N-acetylbacillosamine N-acetyltransferase EC 2.3.1.204: octanoyl-[GcvH]:protein N-octanoyltransferase EC 2.3.1.205: fumigaclavine B O-acetyltransferase EC 2.3.1.206: 3,5,7-trioxododecanoyl-CoA synthase EC 2.3.1.207: β-ketodecanoyl-[acyl-carrier-protein] synthase EC 2.3.1.208: 4-hydroxycoumarin synthase EC 2.3.1.209: dTDP-4-amino-4,6-dideoxy-D-glucose acyltransferase EC 2.3.1.210: dTDP-4-amino-4,6-dideoxy-D-galactose acyltransferase EC 2.3.1.211: bisdemethoxycurcumin synthase EC 2.3.1.212: benzalacetone synthase EC 2.3.1.213: cyanidin 3-O-(6-O-glucosyl-2-O-xylosylgalactoside) 6′′′-O-hydroxycinnamoyltransferase EC 2.3.1.214: pelargonidin 3-O-(6-caffeoylglucoside) 5-O-(6-O-malonylglucoside) 4′′′-malonyltransferase EC 2.3.1.215: anthocyanin 3-O-glucoside 6-O-hydroxycinnamoyltransferase EC 2.3.1.216: 5,7-dihydroxy-2-methylchromone synthase EC 2.3.1.217: curcumin synthase EC 2.3.1.218: phenylpropanoylacetyl-CoA synthase EC 2.3.1.219: demethoxycurcumin synthase EC 2.3.1.220: 2,4,6-trihydroxybenzophenone synthase EC 2.3.1.221: noranthrone synthase EC 2.3.1.222: phosphate propanoyltransferase EC 2.3.1.223: 3-oxo-5,6-didehydrosuberyl-CoA thiolase EC 2.3.1.224: acetyl-CoA-benzylalcohol acetyltransferase EC 2.3.1.225: protein S-acyltransferase EC 2.3.1.226: carboxymethylproline synthase EC 2.3.1.227: GDP-perosamine N-acetyltransferase EC 2.3.1.228: isovaleryl-homoserine lactone synthase EC 2.3.1.229: 4-coumaroyl-homoserine lactone synthase EC 2.3.1.230: 2-heptyl-4(1H)-quinolone synthase EC 2.3.1.231: tRNAPhe {7-[3-amino-3-(methoxycarbonyl)propyl]wyosine37 -N}-methoxycarbonyltransferase EC 2.3.1.232: methanol O-anthraniloyltransferase EC 2.3.1.233: 1,3,6,8-tetrahydroxynaphthalene synthase EC 2.3.1.234: N6-L-threonylcarbamoyladenine synthase EC 2.3.1.235: tetracenomycin F2 synthase EC 2.3.1.236: 5-methylnaphthoic acid synthase EC 2.3.1.237: neocarzinostatin naphthoate synthase EC 2.3.1.238: monacolin J acid methylbutanoate transferase EC 2.3.1.239: 10-deoxymethynolide synthase EC 2.3.1.240: narbonolide synthase EC 2.3.1.241: Kdo2-lipid IVA lauroyltransferase EC 2.3.1.242: Kdo2-lipid IVA palmitoleoyltransferase EC 2.3.1.243: lauroyl-Kdo2-lipid IVA myristoyltransferase EC 2.3.1.244: 2-methylbutanoate polyketide synthase EC 2.3.1.245: 3-hydroxy-5-phosphooxypentane-2,4-dione thiolase EC 2.3.1.246: 3,5-dihydroxyphenylacetyl-CoA synthase EC 2.3.1.247: 3-keto-5-aminohexanoate cleavage enzyme EC 2.3.1.248: spermidine disinapoyl transferase EC 2.3.1.249: spermidine dicoumaroyl transferase EC 2.3.1.250: [Wnt protein] O-palmitoleoyl transferase EC 2.3.1.251: lipid IVA palmitoyltransferase EC 2.3.1.252: mycolipanoate synthase EC 2.3.1.253: phloroglucinol synthase EC 2.3.1.254: N-terminal methionine Nα-acetyltransferase NatB EC 2.3.1.255: N-terminal amino-acid Nα-acetyltransferase NatA EC 2.3.1.256: N-terminal methionine Nα-acetyltransferase NatC EC 2.3.1.257: N-terminal L-serine Nα-acetyltransferase NatD EC 2.3.1.258: N-terminal methionine Nα-acetyltransferase NatE EC 2.3.1.259: N-terminal methionine Nα-acetyltransferase NatF EC 2.3.1.260: tetracycline polyketide synthase EC 2.3.1.261: (4-hydroxyphenyl)alkanoate synthase EC 2.3.1.262: anthraniloyl-CoA anthraniloyltransferase EC 2.3.1.263: 2-amino-4-oxopentanoate thiolase EC 2.3.1.264: β-lysine N6-acetyltransferase EC 2.3.1.265: phosphatidylinositol dimannoside acyltransferase EC 2.3.1.266: [ribosomal protein S18]-alanine N-acetyltransferase EC 2.3.1.267: [ribosomal protein S5]-alanine N-acetyltransferase EC 2.3.1.268: ethanol O-acetyltransferase EC 2.3.1.269: apolipoprotein N-acyltransferase EC 2.3.1.270: lyso-ornithine lipid O-acyltransferase EC 2.3.1.271: L-glutamate-5-semialdehyde N-acetyltransferase EC 2.3.1.272: 2-acetylphloroglucinol acetyltransferase EC 2.3.1.273: diglucosylglycerate octanoyltransferase EC 2.3.1.274: phosphate acyltransferase EC 2.3.1.275: acyl phosphate:glycerol-3-phosphate acyltransferase EC 2.3.1.276: galactosamine-1-phosphate N-acetyltransferase EC 2.3.1.277: 2-oxo-3-(phosphooxy)propyl 3-oxoalkanoate synthase EC 2.3.1.278: mycolipenoyl-CoA—2-(long-chain-fatty acyl)-trehalose mycolipenoyltransferase EC 2.3.1.279: long-chain-acyl-CoA—trehalose acyltransferase EC 2.3.1.280: (aminoalkyl)phosphonate N-acetyltransferase EC 2.3.1.281: 5-hydroxydodecatetraenal polyketide synthase EC 2.3.1.282: phenolphthiocerol/phthiocerol/phthiodiolone dimycocerosyl transferase EC 2.3.1.283: 2′-acyl-2-O-sulfo-trehalose (hydroxy)phthioceranyltransferase EC 2.3.1.284: 3′-(hydroxy)phthioceranyl-2′-palmitoyl(stearoyl)-2-O-sulfo-trehalose (hydroxy)phthioceranyltransferase EC 2.3.1.285: (13S,14R)-1,13-dihydroxy-N-methylcanadine 13-O-acetyltransferase EC 2.3.1.286: protein acetyllysine N-acetyltransferase EC 2.3.1.287: phthioceranic/hydroxyphthioceranic acid synthase EC 2.3.1.288: 2-O-sulfo trehalose long-chain-acyltransferase EC 2.3.1.289: aureothin polyketide synthase system EC 2.3.1.290: spectinabilin polyketide synthase system EC 2.3.1.291: sphingoid base N-palmitoyltransferase EC 2.3.1.292: (phenol)carboxyphthiodiolenone synthase EC 2.3.1.293: meromycolic acid 3-oxoacyl-(acyl carrier protein) synthase I EC 2.3.1.294: meromycolic acid 3-oxoacyl-(acyl carrier protein) synthase II EC 2.3.1.295: mycoketide-CoA synthase EC 2.3.1.296: ω-hydroxyceramide transacylase EC 2.3.1.297: very-long-chain ceramide synthase EC 2.3.1.298: ultra-long-chain ceramide synthase EC 2.3.1.299: sphingoid base N-stearoyltransferase EC 2.3.1.300: branched-chain β-ketoacyl-[acyl-carrier-protein] synthase EC 2.3.1.301: mycobacterial β-ketoacyl-[acyl carrier protein] synthase III EC 2.3.1.302: hydroxycinnamoyl-CoA:5-hydroxyanthranilate N-hydroxycinnamoyltransferase EC 2.3.1.303: α-L-Rha-(1→2)-α-D-Man-(1→2)-α-D-Man-(1→3)-α-D-Gal-PP-Und 2IV-O-acetyltransferase EC 2.3.1.304: poly[(S)-3-hydroxyalkanoate] polymerase
=== Center for Structural Biology === The Center for Structural Biology (CSB) is a "collaboratory" for X-ray crystallography, crystallization and protein engineering, and is a comprehensive structural biology resource for researchers at the University of Michigan and surrounding area. The center includes:
While electronic review later indicated the serve was out, Roland Garros does not use Hawk-Eye as an official officiating tool; instead, the technology is used exclusively for television broadcasts. It is noted that the broadcast version of Hawk-Eye operates with significantly lower precision than the official Electronic Line Calling (ELC) systems installed at other tournaments, leaving open the possibility that the umpire's ruling on the clay mark was accurate. However, the overrule generated controversy. Had the call not been overturned, Zverev would have broken back. Tennis commentator Robbie Koenig and former world No. 1 Andy Roddick disagreed with the overrule. Zverev would go on to lose the fifth set, giving up his two-sets-to-one lead and finishing runner-up to Carlos Alcaraz, who collected his maiden French Open title. In Halle, Zverev reached the semifinals after collecting wins against Oscar Otte, Lorenzo Sonego, and Arthur Fils, losing to Hubert Hurkacz in straight sets. At Wimbledon, Zverev beat Roberto Carballés Baena, Marcos Giron, and Cameron Norrie before losing to Taylor Fritz in the fourth round. His third-set tiebreak with Norrie was noted as one of the longest tiebreaks of the tournament, with Zverev prevailing 17–15 after 26 minutes. Back on clay, Zverev reached the final in Hamburg, losing to Arthur Fils in three sets. At the Olympic Games in Paris, Zverev represented Team Germany as defending champion.
The development of necrotizing myopathy after statin exposure is insufficient to make the diagnosis. Testing must first exclude other causes of myositis and necrotizing myopathy. A muscle biopsy consistent with SAAM will demonstrate muscle cell death with muscle fiber regeneration and typically has few inflammatory cells. Immunohistochemistry testing may demonstrate additional pathologic features of SAAM. Such findings include the presence of endothelial cell membrane attack complex in non-necrotic muscle fibers and MHC class I expression. Antibodies against HMG-CoA reductase occur in 94% of affected individuals. These antibodies are known to also occur in people who do not take statin medications. Conversely, these antibodies are absent in people who take statin medications but do not have myopathy. Thus, the presence of anti-HMG CoA reductase antibodies in someone who uses a statin and has myopathy strongly supports the diagnosis. CK levels increase to 10-100 times above normal (2000–20,000 IU/L) in more than 90% of cases. Electromyography (EMG) typically demonstrates a myopathic pattern of findings. Muscle swelling may be seen on MRI imaging.
Sources: en.wikipedia.org
== Selected bibliography == Daly, Marie M.; Mirsky, A.E. (June 1949). "Chromatography of Purines and Pyrimidines on Starch Columns". Journal of Biological Chemistry. 179 (2): 981–982. doi:10.1016/S0021-9258(19)51291-1. PMID 18150028. Daly, M.M.; Allfrey, V.G.; Mirsky, A.E. (May 20, 1950). "Purine and Pyrimidine Contents of Some Desoxypentose Nucleic Acids" (PDF). Journal of General Physiology. 33 (5): 497–510. doi:10.1085/jgp.33.5.497. PMC 2147206. PMID 15422104. Daly, Marie; Mirsky, A.E.; Ris, Hans (March 20, 1951). "The Amino Acid Composition and Some Properties of Histones" (PDF). The Journal of General Physiology. 34 (4): 439–450. doi:10.1085/jgp.34.4.439. PMC 2147226. PMID 14824510. Daly, Marie M.; Mirsky, A.E. (November 1952). "Formation of Protein in the Pancreas". Journal of General Physiology. 36 (2): 243–254. doi:10.1085/jgp.36.2.243. PMC 2147369. PMID 13011280. Daly, Marie M.; Allfrey, V.G.; Mirsky, A.E. (November 1952). "Uptake of Glycine-N15 by Components of Cell Nuclei" (PDF). Journal of General Physiology. 36 (2): 173–179. doi:10.1085/jgp.36.2.173. PMC 2147362. PMID 13011275. Allfrey, V.; Daly, M.M.; Mirsky, A.E. (November 20, 1953). "Synthesis of protein in the pancreas. II. The role of ribonucleoprotein in protein synthesis". Journal of General Physiology. 37 (2): 157–175. doi:10.1085/jgp.37.2.157. PMC 214743. PMID 13109153. Mirsky, A.E.; Allfrey, V.G.; Daly, M.M. (September 1954). "The Uptake of N15-Labelled Glycine by Liver Proteins". Journal of Histochemistry and Cytochemistry. 2 (5): 376–377. doi:10.1177/2.5.376. PMID 13192326. S2CID 40223958.
=== I2 receptor === The I2 receptor binding sites have been defined as being selective binding sites inhibited by the antagonist idazoxan that are not blocked by catecholamines. The major binding site is located on the outer mitochondrial membrane, and is proposed to be an allosteric site on monoamine oxidase, while another binding site has been found to be brain creatine kinase. Other known binding sites have yet to be characterized as of 2017. Preliminary research in rodents suggests that I2 receptor agonists may be effective in chronic, but not acute pain, including fibromyalgia. I2 receptor activation has also been shown to decrease body temperature, potentially mediating neuroprotective effects seen in rats. The only known antagonist for the receptor is idazoxan, which is non-selective.
== Pregnancy == Scleroderma in pregnancy is a complex situation; it increases the risk to both mother and child. Overall, scleroderma is associated with reduced fetal weight for gestational age. The treatment for scleroderma often includes known teratogens such as cyclophosphamide, methotrexate, mycophenolate, etc., so careful avoidance of such drugs during pregnancy is advised. In these cases hydroxychloroquine and low-dose corticosteroids might be used for disease control.
Sources: en.wikipedia.org
Primary drying removes ice by sublimation at low pressure and low shelf temperature. Secondary drying removes bound water by raising the shelf temperature, often under the same vacuum. The two stages differ in the water state being removed.
Freezing determines ice crystal size, pore structure, and the concentration of solutes in remaining liquid. Faster freezing generally creates smaller ice crystals and a denser dried matrix. These features affect drying rate and reconstitution behavior.
Lyophilization reduces water content but usually leaves a small amount of water in the dried material. Some water remains bound to solids or trapped in the dried matrix. Very low water targets can require extended secondary drying, which may alter product stability.
Conventional drying uses heat to evaporate water from a material, while lyophilization freezes the material and removes water by sublimation under vacuum. This avoids the liquid phase and reduces thermal damage to sensitive substances. The result is a porous cake that reconstitutes quickly.